Sequential Intravenous Plus Intra-arterial Chemotherapy versus Intra-arterial Chemotherapy in Children with Advanced Unilateral Retinoblastoma

INTRODUCTION: Retinoblastoma is the most common primary intraocular malignancy in children. Intra-arterial chemotherapy improves local drug delivery and globe salvage, but repeated catheterization may damage ocular vessels. Intravenous chemotherapy (IVC) may cause systemic toxicity. This trial will test whether two initial intravenous cycles followed by two intra-arterial cycles preserve efficacy while reducing the burden of each treatment route. METHODS: We will enroll 288 untreated children aged > 3 months and weighing > 5 kg with unilateral American Joint Committee on Cancer (AJCC) cT2N0M0 retinoblastoma in this multicenter, open-label, assessor-masked, randomized noninferiority trial. A central interactive web response system will assign participants 1:1 using variable block randomization stratified by center and cT2a/cT2b stage. The experimental group will receive two cycles of IVC followed by two cycles of intra-arterial chemotherapy (IAC). The control group will receive four cycles of IAC. Focal therapy is permitted. The primary outcome is 2-year progression-free globe salvage assessed over 24 months. PLANNED OUTCOMES: The trial will evaluate whether sequential intravenous plus intra-arterial chemotherapy provides acceptable tumor control while limiting treatment-related harm and resource use in unilateral cT2 disease. The primary outcome is the 2-year progression-free globe salvage rate. Secondary outcomes are 2-year globe salvage, objective response, all-cause mortality, recurrence, intracranial metastasis, local and systemic toxicity, retention of measurable vision, and treatment cost. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000036586; prospectively registered on 24 August 2020.

Authors

Institutions

Publication Details

Journal
Ophthalmology and Therapy
Published
2026-11-17
DOI
https://doi.org/10.1007/s40123-026-01534-7
Primary Topic
Ocular Oncology and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sequential Intravenous Plus Intra-arterial Chemotherapy versus Intra-arterial Chemotherapy in Children with Advanced Unilateral Retinoblastoma

Huanxiao Shi, Rongji Mu, Peiwei Chai, 季迅达 et al.
1 links
Ophthalmology and Therapy
Ocular Oncology and Treatments
article

Sequential Intravenous Plus Intra-arterial Chemotherapy versus Intra-arterial Chemotherapy in Children with Advanced Unilateral Retinoblastoma

Huanxiao Shi, Rongji Mu, Peiwei Chai, 季迅达, Renbing Jia, 范佳燕, Xianqun Fan, Chenhao Yang, Xuyang Wen, Zhangsheng Yu, Minglei Han
article en

Abstract

INTRODUCTION: Retinoblastoma is the most common primary intraocular malignancy in children. Intra-arterial chemotherapy improves local drug delivery and globe salvage, but repeated catheterization may damage ocular vessels. Intravenous chemotherapy (IVC) may cause systemic toxicity. This trial will test whether two initial intravenous cycles followed by two intra-arterial cycles preserve efficacy while reducing the burden of each treatment route. METHODS: We will enroll 288 untreated children aged > 3 months and weighing > 5 kg with unilateral American Joint Committee on Cancer (AJCC) cT2N0M0 retinoblastoma in this multicenter, open-label, assessor-masked, randomized noninferiority trial. A central interactive web response system will assign participants 1:1 using variable block randomization stratified by center and cT2a/cT2b stage. The experimental group will receive two cycles of IVC followed by two cycles of intra-arterial chemotherapy (IAC). The control group will receive four cycles of IAC. Focal therapy is permitted. The primary outcome is 2-year progression-free globe salvage assessed over 24 months. PLANNED OUTCOMES: The trial will evaluate whether sequential intravenous plus intra-arterial chemotherapy provides acceptable tumor control while limiting treatment-related harm and resource use in unilateral cT2 disease. The primary outcome is the 2-year progression-free globe salvage rate. Secondary outcomes are 2-year globe salvage, objective response, all-cause mortality, recurrence, intracranial metastasis, local and systemic toxicity, retention of measurable vision, and treatment cost. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2000036586; prospectively registered on 24 August 2020.

Ophthalmology and Therapy
Shanghai Jiao Tong University (CN), Renji Hospital (CN), XinHua Hospital (CN), Shanghai Ninth People's Hospital (CN), Shanghai First People's Hospital (CN), Children's Hospital of Fudan University (CN)
National Natural Science Foundation of China, Ministry of Education of the People's Republic of China, Shanghai Hospital Development Center
Good health and well-being
Ocular Oncology and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon